TipRanks
Advertisement
Advertisement
Aktis Oncology initiated with an Outperform at BMO Capital
PremiumThe FlyAktis Oncology initiated with an Outperform at BMO Capital
29d ago
Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M
Premium
The Fly
Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M
1M ago
Fifteen new option listings on July 15th
Premium
The Fly
Fifteen new option listings on July 15th
2M ago
Early Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
PremiumRatingsEarly Clinical Data and Differentiated Miniprotein Platform Underpin Buy Rating on Aktis for B7-H3 Radiopharmaceutical in mCRPC
4M ago
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
Premium
Ratings
Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update
4M ago
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
Premium
Ratings
Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity
4M ago
Aktis Oncology initiated with an Outperform at William Blair
PremiumThe FlyAktis Oncology initiated with an Outperform at William Blair
5M ago
Aktis Oncology appoints Gormley as independent director of Board of Directors
Premium
The Fly
Aktis Oncology appoints Gormley as independent director of Board of Directors
5M ago
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
Premium
Ratings
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100